Key result
NAFLD is linked to a ~34% higher plasma atherogenic index compared to healthy controls.
Why the study?
The role of the plasma atherogenic index (PAI) and its relationship with metabolic components in non-alcoholic fatty liver disease (NAFLD) is not clear.
Cross-Sectional (n=234)
No
The plasma atherogenic index is elevated in patients with NAFLD and correlates with metabolic syndrome components, suggesting its potential utility as a marker for cardiovascular risk in this population.
Answers are grounded in this paper and cite their sources.
Elevated atherogenic index in NAFLD; leaves open its utility as a cardiovascular risk marker pending prospective validation.
Background Plasma atherogenic index (PAI) is a novel index investigated in recent years related to cardiovascular disease and atherosclerosis. The role of PAI is not clear in non-alcoholic fatty liver disease (NAFLD). This study aimed to examine the role of PAI in patients with NAFLD and its relationship with metabolic components. Material and Methods This study was designed as a retrospective study, and the patients' files admitted to the Internal Medicine unit were retrospectively scanned. Within the scope of the study, demographic and laboratory data of the groups with and without NAFLD were compared. Results A total of 234 patients were evaluated, 159 of which were NAFLD (age: 39.52 ± 10.38 years) and 75 controls (age: 38.07 ± 12.11 years) (p = 0.374). PAI level was statistically significantly higher in the NAFLD group compared to the control group (p = 0.006). In the whole group correlation analysis, PAI level and body mass index (p < 0.001, r = 0.363), waist circumference (p < 0.001, r = 0.366), systolic blood pressure (p < 0.001, r = 0.333), diastolic blood pressure (p = 0.001, r = 0.210), ALT (p < 0.001, r = 0.312), AST (p = 0.005, r = 0.182), fasting plasma glucose (p = 0.017, r = 0.157) and insulin resistance (p < 0.001, r = 0.302) values were positively correlated. Conclusions PAI level was higher in patients with NAFLD; this index was associated with other metabolic components, especially insulin resistance. This indicates that the PAI level may be associated with clinical progression in the pathogenesis and course of the disease.
No takes yet. Share an insight, caveat, or question.
Kırık et al. (2023) conducted a cross-sectional in Non-alcoholic fatty liver disease (NAFLD) (n=234). Non-alcoholic fatty liver disease (NAFLD) vs. Healthy controls was evaluated on Plasma atherogenic index (PAI) level (p=0.006). Plasma atherogenic index levels were higher in patients with non-alcoholic fatty liver disease compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: